Elevation Oncology Unveils Promising HER3 ADC Candidate for Multiple Cancer Types Elevation Oncology advances cancer treatment with new HER3 ADC candidate EO-1022, leveraging proven antibody tech and Synaffix platform for breast, lung, and pancreatic cancers.

#ELEV #LZAGY Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

#investing #news #StockMarket

www.stocktitan.net/news/ELEV/elevation-onco...